Researchers are investigating the potential of CRISPR in relation to Down syndrome.

In the latest close session, CRISPR Therapeutics AG (CRSP) was down 1.81% at $60.77. This change lagged the S&P 500's daily loss of 0.45%. Meanwhile, the Dow experienced a drop of 0.25%, and the ...

The practice of genetic modification is as old as humanity. For thousands of years, humans have bred crops, livestock and even pets that possess desirable traits. This selective process, which alters ...

Northwestern scientists have developed a new nanostructure that supercharges CRISPR’s ability to safely and efficiently enter cells, potentially unlocking its full power to treat genetic diseases. By ...

Discover the top CRISPR companies driving innovation in gene editing, from biotech pioneers to promising start-ups shaping the future of medicine and genetics.

Vertex Pharmaceuticals plans to sell a gene-editing treatment for sickle-cell disease. A patent on CRISPR could stand in the way. That’s a real nice CRISPR cure you have there. It would be a pity if ...

With the first medical therapy approved and systems like CRISPR-Cas showing up in complex cells, there’s a lot happening in the genome editing field. By Amber Dance/Knowable Magazine Published Jan 26, ...

Using a genome-wide CRISPR screen and AI analysis, researchers uncovered unexpected psoriasis drug targets, including the ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $54.92, demonstrating a +1.74% change from the preceding day's closing price. The stock outpaced the S&P 500's daily loss of 0.05%. At ...